The expression of ζ-chain of the T cell receptor as prognostic marker for patients with head and neck cancer;Die expression der ζ-kette des T-zell-rezeptors als prognosemarker bei kopf-hals-karzinomen

Laryngo- Rhino- Otologie

Volumn 81, Issue 7, 2002, Pages 516-520

  Muller D ^a   Lang, S ^a   Roskrow, M ^b   Wollenberg, Barbara ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Lazard Freres and Co Life Sciences Group   (United States)

Author keywords

chain; Genetherapy; Immunotherapy; SCCHN; Squamous cell carcinoma of the head and neck

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; ANTIGEN T CELL RECEPTOR, ZETA CHAIN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; FOLLOW UP; HEAD AND NECK TUMOR; IMMUNOLOGY; LYMPHOCYTE; PATHOLOGY; REOPERATION; TUMOR ESCAPE; TUMOR RECURRENCE;

CARCINOMA, SQUAMOUS CELL; ENGLISH ABSTRACT; FOLLOW-UP STUDIES; HUMAN; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OTORHINOLARYNGOLOGIC NEOPLASMS; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL; REOPERATION; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL; HUMANS;

EID: 0036021258     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-33289     Document Type: Article

References (22)

1. Causes of immunosuppression in squamous cell carcinoma of the head and neck
2. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor specific immunity
3. Expression of the T cell antigen receptor zeta chain following activation is controlled at distinct checkpoints. Implications for cell surface receptor down-modulation and re-expression
4. The extracellular domain of the zeta-chain is essential for TCR function
5. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present
6. Caspase-mediated degradation of T-cell receptor zeta-chain
7. T-cell receptor-chain expression on tumorinfiltration lymphocytes from renal cell carcinoma
8. Expression of TCR zeta chain of tumor associated lymphocytes from malignant pleural effusions
9. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma
10. Absent or low expression of the zeta chain in Tcells at the tumor site correlates with poor survival in patients with oral carcinoma
11. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma
12. The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26
13. Comparative study on the effect of phosphorylated TCR zeta chain ITAM sequences on early activation events in Jurkat T cells
14. Alterations in T cell receptor and signal transduction molecules in melanoma patients
15. T cell signaling abnormalities in systemic lupus erythematosus are associated with increased mutations/polymorphisms and splice variants of T cell receptor zeta chain messenger RNA
16. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28
17. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma
18. Clinical significance of decreased-chain expression in peripheral blood lymphocytes of patients with head and neck cancer
19. Tumor-induced apoptosis of T lymphocytes: Elucidation of intracellular apoptotic events
20. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes
21. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy
22. The decreased expression of CD3 ζ-chains in cancer patients is not reversed by IL2 administration